Journal article
Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists
Journal of pharmacy & pharmaceutical sciences, Vol.29, 15713
03/01/2026
DOI: 10.3389/jpps.2026.15713
PMCID: PMC12995819
PMID: 41859284
Abstract
Asthma and allergies are closely related conditions affecting millions of people around the world. Current treatment options cover many classes of drugs for both acute and ongoing conditions. β2-agonists, leukotriene modifiers, and corticosteroids represent some of the common types of drugs utilized in asthma management. These medications are often delivered via inhalation, oral, or parenteral methods, but each of these modalities faces challenges due to improper technique with inhalers, lessened oral bioavailability due to first-pass metabolism, and reduced compliance of injectable medicines. Transdermal drug delivery may offer a beneficial route of administration that overcomes these barriers as a painless, self-administered form that bypasses first-pass metabolism and can reduce dosing frequency with longer drug release profiles and reduced fluctuations in plasma drug levels. In this two-part mini-review series we will summarize the current literature on transdermal systems for asthma and allergy therapy. Here in Part 1, we cover β2-agonists and discuss the potential of transdermal systems for these drugs. While the body of work with transdermal β2-agonists for asthma treatment is limited, there is still evidence that transdermal systems for asthma has potential to greatly shift the field of asthma therapeutics.
Details
- Title: Subtitle
- Rethinking asthma therapy, part 1: transdermal delivery of β2-agonists
- Creators
- Joseph Correa - Io Therapeutics (United States)Nicole K. Brogden - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of pharmacy & pharmaceutical sciences, Vol.29, 15713
- DOI
- 10.3389/jpps.2026.15713
- PMID
- 41859284
- PMCID
- PMC12995819
- NLM abbreviation
- J Pharm Pharm Sci
- ISSN
- 1482-1826
- eISSN
- 1482-1826
- Publisher
- Frontiers Media S.A
- Grant note
- National Institutes of Health: 1R35GM149337 Iowa Biotech Training Program - T32 grantNational Institute of General Medical Sciences Predoctoral Institutional Research Training Grant: NIGMS T32 GM152268 Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Institutes of Health awards 1R35GM149337. Funding to support Joseph Correa's efforts was partially provided by the Iowa Biotech Training Program as funded by a T32 grant awarded by the National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant (NIGMS T32 GM152268) and administered by the Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa.
- Language
- English
- Date published
- 03/01/2026
- Academic Unit
- Dermatology; Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9985143132102771
Metrics
1 Record Views